NL300415I2 - - Google Patents

Download PDF

Info

Publication number
NL300415I2
NL300415I2 NL300415C NL300415C NL300415I2 NL 300415 I2 NL300415 I2 NL 300415I2 NL 300415 C NL300415 C NL 300415C NL 300415 C NL300415 C NL 300415C NL 300415 I2 NL300415 I2 NL 300415I2
Authority
NL
Netherlands
Application number
NL300415C
Other versions
NL300415I1 (nl
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of NL300415I1 publication Critical patent/NL300415I1/nl
Publication of NL300415I2 publication Critical patent/NL300415I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NL300415C 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn NL300415I1 (nl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine
PCT/EP2000/002468 WO2000056360A2 (en) 1999-03-19 2000-03-17 Vaccine against antigens from bacteriae

Publications (2)

Publication Number Publication Date
NL300415I1 NL300415I1 (nl) 2009-12-01
NL300415I2 true NL300415I2 (nl) 2016-12-13

Family

ID=27451884

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300415C NL300415I1 (nl) 1999-03-19 2009-09-24 Vaccin tegen antigenen van bacteriƫn

Country Status (32)

Country Link
US (8) US20030147922A1 (nl)
EP (6) EP1163000B1 (nl)
JP (4) JP2002539273A (nl)
KR (3) KR100798212B1 (nl)
CN (3) CN1192798C (nl)
AR (3) AR022964A1 (nl)
AT (3) ATE346608T1 (nl)
AU (3) AU750788B2 (nl)
BE (1) BE1025464I2 (nl)
BR (4) BR0009166A (nl)
CA (3) CA2366152A1 (nl)
CY (3) CY1107561T1 (nl)
CZ (3) CZ20013378A3 (nl)
DE (4) DE60038166T2 (nl)
DK (2) DK1162999T3 (nl)
ES (3) ES2300255T3 (nl)
FR (1) FR10C0008I2 (nl)
HK (3) HK1043731B (nl)
HU (4) HU229968B1 (nl)
IL (5) IL145045A0 (nl)
LU (1) LU91652I2 (nl)
MX (1) MXPA01009452A (nl)
MY (2) MY125387A (nl)
NL (1) NL300415I1 (nl)
NO (4) NO20014322L (nl)
NZ (3) NZ513841A (nl)
PL (3) PL203917B1 (nl)
PT (2) PT1163000E (nl)
SI (2) SI1162999T1 (nl)
TR (3) TR200102736T2 (nl)
TW (3) TWI281403B (nl)
WO (3) WO2000056360A2 (nl)

Families Citing this family (273)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
WO1997025429A1 (en) 1996-01-04 1997-07-17 Rican Limited Helicobacter pylori bacterioferritin
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
NZ508927A (en) 1998-05-22 2003-12-19 Ottawa Health Research Inst Methods and products for inducing mucosal immunity
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP1163000B1 (en) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccine against antigens from bacteriae
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2189473A3 (en) 2000-10-27 2010-08-11 Novartis Vaccines and Diagnostics S.r.l. Nucleic and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
OA12590A (en) 2001-01-23 2006-06-08 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine.
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ATE406912T1 (de) 2001-12-12 2008-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
DE60328481D1 (de) * 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic Schleimhautapplizierter impfstoff, der das adjuvanz chitosan und menigokokkenantigene enthƤlt
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
BR0310042A (pt) * 2002-05-14 2005-04-05 Chiron Srl Vacinas de combinaĆ§Ć£o mucosal para meningite bacteriana
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
PT2353608T (pt) 2002-10-11 2020-03-11 Novartis Vaccines And Diagnostics S R L Vacinas de polipĆ©ptidos para protecĆ§Ć£o alargada contra linhagens meningocĆ³cicas hipervirulentas
JP5116971B2 (ja) * 2002-10-15 2013-01-09 ć‚¤ćƒ³ć‚æćƒ¼ć‚»ćƒ« ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼¢ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć‚’ć‚³ćƒ¼ćƒ‰ć™ć‚‹ę øé…ø态ļ½‚ē¾¤é€£éŽ–ēƒčŒć®ęŽ„ē€å› å­ć€ćŠć‚ˆć³ćć®ä½æē”Ø
EP1556477B1 (en) 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Drying process
MXPA05005045A (es) 2002-11-12 2005-07-01 Brigham & Womens Hospital Vacuna de polisacarido para infecciones estafilococicas.
CA2506318C (en) 2002-11-15 2011-07-12 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2004053104A2 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5ā€™ cpg nucleic acids and methods of use
AU2003299994A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Immunogenic compositions containing phospholpid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
CN102302776B (zh) * 2003-01-30 2014-06-18 čÆŗ华ē–«č‹—å’ŒčÆŠę–­ęœ‰é™å…¬åø ęŠ—å¤šē§č„‘č†œē‚ŽēƒčŒč”€ęø…ē»„ēš„åÆę³Øå°„ę€§ē–«č‹—
AU2004220590B2 (en) * 2003-03-07 2010-02-18 Inhibitex, Inc. Polysaccharide - Staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
CA2812817C (en) * 2003-03-13 2016-12-20 Glaxosmithkline Biologicals S.A. Method of detoxification of pneumolysin
CA2520124A1 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of benzazole compounds for immunopotentiation
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogƩnicas a base de micropartƭculas que comprenden toxoide adsorbido y un antƭgeno que contiene un polisacƔrido
CA2885040C (en) * 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
CA2575548A1 (en) 2004-07-29 2006-07-27 John L. Telford Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
MX2007008785A (es) 2005-01-27 2008-02-15 Childrens Hosp & Res Ct Oak Vacunas de vesicula basadas en gna1870 para proteccion de amplio espectro contra padecimientos causados por neisseria meningitidis.
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ597685A (en) 2005-02-18 2013-12-20 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
NZ560929A (en) 2005-02-18 2009-12-24 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102564388B1 (ko) * 2005-04-08 2023-08-08 ģ™€ģ“ģ–“ģ“° ģ—˜ģ—˜ģ”Ø ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
US20070184072A1 (en) * 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US8119146B2 (en) 2005-04-18 2012-02-21 Angelica Medina-Selby Expressing hepatitis B virus surface antigen for vaccine preparation
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP1931380A2 (en) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Multiple vaccination including serogroup c meningococcus
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
WO2007081447A2 (en) 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa ꖰē©Žēµ„合ē‰©
MY160199A (en) * 2005-12-22 2017-02-28 Glaxosmithkline Biologicals Sa Pneumococcal polysaccharide conjugate vaccine
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
NZ569417A (en) * 2006-01-17 2012-04-27 Arne Forsgren A novel surface exposed haemophilus influenzae protein (protein E; pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 ē¦å·žę˜Œę™–ē”Ÿē‰©å·„ēØ‹ęœ‰é™å…¬åø č‚ŗē‚Žé“¾ēƒčŒå¤šē³–-å¤–č†œč›‹ē™½ē»“合ē–«č‹—åŠåˆ¶å¤‡ę–¹ę³•
KR101947794B1 (ko) * 2006-03-17 2019-02-13 ė” ź±°ė²„ėؼķŠø ģ˜¤ėøŒ ė” ģœ ė‚˜ģ“ķ‹°ė“œ ģŠ¤ķ…Œģ“ģø  ģ˜¤ėøŒ ģ•„ė©”ė¦¬ģ¹“ ģ—ģ¦ˆ ė ˆķ”„ė¦¬ģ  ķ‹°ė“œ ė°”ģ“ ė” ģ„øķ¬ėŸ¬ķ…Œė¦¬ ģ˜¤ėøŒ ė” ė””ķŒŒķŠøėؼķŠø ģ˜¤ėøŒ ķ—¬ģŠ¤ ģ•¤ė“œ ķœ“ėؼ ģ„œė¹„ģ‹œģ¦ˆ ė³µķ•© ė‹¤ź°€ ė©“ģ—­ģ›ģ„± ģ½˜ģ„¬ź²Œģ“ķŠøģ˜ ģ œģ”° ė°©ė²•
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
EP2357184B1 (en) 2006-03-23 2015-02-25 Novartis AG Imidazoquinoxaline compounds as immunomodulators
CN103169960A (zh) * 2006-03-30 2013-06-26 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø 免ē–«åŽŸę€§ē»„合ē‰©
TWI494124B (zh) * 2006-03-30 2015-08-01 Glaxosmithkline Biolog Sa 免ē–«åŽŸēµ„合ē‰©
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
WO2008020335A2 (en) * 2006-06-09 2008-02-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
AU2007285484B2 (en) 2006-08-16 2013-05-02 Novartis Ag Immunogens from uropathogenic Escherichia coli
ES2346929T3 (es) * 2006-10-10 2010-10-21 Wyeth Llc Procedimientos mejorados para la separacion de polisacaridos de streptococcus pneumoniae de tipo 3.
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
DK2167121T3 (en) * 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009034473A2 (en) 2007-09-12 2009-03-19 Novartis Ag Gas57 mutant antigens and gas57 antibodies
WO2009050586A1 (en) 2007-10-19 2009-04-23 Novartis Ag Meningococcal vaccine formulations
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn IMMUNOREGULATORY COMPOUNDS AND RELATED COMPOSITIONS AND METHODS
ES2664753T3 (es) 2007-12-07 2018-04-23 Glaxosmithkline Biologicals Sa Composiciones de inducciĆ³n de respuestas inmunes
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
CN101977926B (zh) 2007-12-21 2014-10-08 čÆŗåŽč‚”ä»½ęœ‰é™å…¬åø 链ēƒčŒęŗ¶č”€ē“ oēš„ēŖå˜å½¢å¼
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
ES2557282T3 (es) 2008-03-10 2016-01-25 Children's Hospital & Research Center At Oakland ProteĆ­nas quimĆ©ricas de uniĆ³n al factor H (fHBP) que contienen un dominio B heterĆ³logo, y mĆ©todos de uso
WO2010011284A2 (en) 2008-07-21 2010-01-28 The Brigham And Women's Hospital, Inc. Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
DK2349520T3 (en) 2008-10-27 2016-08-15 Glaxosmithkline Biologicals Sa Purification Procedure for Group A Streptococcus Carbohydrate
KR101644221B1 (ko) 2008-12-09 2016-07-29 ķ™”ģ“ģž ė°±ģ‹ ģŠ¤ ģ—˜ģ—˜ģ”Ø ļ¼©ļ½‡ļ¼„ ļ¼£ļ¼Øļ¼“ ķŽ©ķ‹°ė“œ ė°±ģ‹ 
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
MX2011007456A (es) 2009-01-12 2011-08-03 Novartis Ag Antigenos del dominio de proteina de superficie de union a colageno tipo b (can_b) en vacunas contra bacteria gram positiva.
CA2756533A1 (en) 2009-03-24 2010-09-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
CA2756522C (en) 2009-03-24 2018-06-26 Novartis Ag Adjuvanting meningococcal factor h binding protein
SI2510947T1 (sl) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Sestavki za imunizacijo proti Staphylococcus aureus
US8668911B2 (en) 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
NZ597191A (en) 2009-06-22 2013-11-29 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
SG10201406520YA (en) 2009-06-22 2014-11-27 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
PE20120817A1 (es) 2009-07-30 2012-07-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos
EP3017828A1 (en) 2009-08-27 2016-05-11 GlaxoSmithKline Biologicals SA Hybrid polypeptides including meningococcal fhbp sequences
MY163512A (en) * 2009-09-03 2017-09-15 Pfizer Vaccines Llc Pcsk9 vaccine
KR20120081587A (ko) 2009-09-10 2012-07-19 ė…øķŒŒė„“ķ‹°ģŠ¤ ģ•„ź²Œ źø°ė„ ģ§ˆė³‘ģ— ėŒ€ķ•œ ģ”°ķ•© ė°±ģ‹ 
US20130022633A1 (en) 2009-10-27 2013-01-24 University Of Florence MENINGOCOCCAL fHBP POLYPEPTIDES
EP2493498B1 (en) 2009-10-30 2017-03-22 GlaxoSmithKline Biologicals SA Purification of staphylococcus aureus type 5 and type 8 capsular saccharides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
SG10201506160VA (en) 2009-12-17 2015-09-29 Fina Biosolutions Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
CN107412754A (zh) 2009-12-22 2017-12-01 唞尔德克ę–Æ医ē–—å…¬åø ē–«č‹—ē»„合ē‰©
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
AU2011238670B2 (en) 2010-03-30 2015-04-23 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
DK2555753T3 (en) 2010-04-07 2018-11-26 California Inst Of Techn Vesicle for delivering a compound to a mucosal membrane as well as corresponding compositions, methods and systems
JP2013530949A (ja) * 2010-05-20 2013-08-01 ć‚Ø惫 ćƒ©ć‚¦ćƒ³ćƒ‰ ć‚øćƒ„ćƒ¼ćƒ³ ęŠ—åŽŸē‰¹ē•°ēš„ļ¼“ļ½’ļ½…ļ½‡äø¦ć³ć«é–¢é€£ć™ć‚‹ēµ„ęˆē‰©ć€ę–¹ę³•åŠć³ć‚·ć‚¹ćƒ†ćƒ 
KR20130121699A (ko) 2010-05-28 2013-11-06 ķ…ŒķŠøė¦¬ģŠ¤ ģ˜Øė¼ģø, ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģƒķ˜øģž‘ģš© ķ˜¼ģ„± ė¹„ė™źø° ģ»“ķ“Øķ„° ź²Œģž„ źø°ė°˜źµ¬ģ”°
SI2575870T1 (sl) * 2010-06-04 2017-01-31 Wyeth Llc Formulacije cepiva
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
AU2011268507B2 (en) 2010-06-25 2014-08-14 Novartis Ag Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
WO2012085668A2 (en) 2010-12-24 2012-06-28 Novartis Ag Compounds
ES2612511T3 (es) 2011-01-27 2017-05-17 Glaxosmithkline Biologicals Sa Nanoemulsiones de adyuvante con inhibidores de cristalizaciĆ³n
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolĆ­pidos
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
US20130203980A1 (en) 2011-05-06 2013-08-08 Petr Gennadievich Aparin Exopolysaccharide of shigella sonnei bacteria, method for producing same, vaccine and pharmaceutical composition containing same
JP6499446B2 (ja) 2011-06-24 2019-04-10 ć‚Ø惔惃惈ć‚øć‚§ćƒć‚·ć‚¹ćƒ»ć‚¤ćƒ³ć‚³ćƒ¼ćƒćƒ¬ćƒ¼ćƒ†ćƒƒćƒ‰ ęŠ—åŽŸē‰¹ē•°ēš„免ē–«ćƒ¢ć‚øćƒ„ćƒ¬ćƒ¼ć‚æćƒ¼ćØ恗恦éøęŠžę‹…ä½“ć€ćƒ“ć‚æćƒŸćƒ³ć€ć‚æćƒ³ćƒ‹ćƒ³ćŠć‚ˆć³ćƒ•ćƒ©ćƒœćƒŽć‚¤ćƒ‰ć®ēµ„ćæåˆć‚ć›ć‚’å«ęœ‰ć™ć‚‹åŒ»č–¬ēµ„ęˆē‰©
JP6088507B2 (ja) 2011-07-08 2017-03-01 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ćƒćƒ­ć‚·ćƒ³ćƒ©ć‚¤ć‚²ćƒ¼ć‚·ćƒ§ćƒ³ć®ę–¹ę³•
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
EP2757882B1 (en) 2011-09-22 2020-11-04 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
CN104080479B (zh) 2011-11-07 2019-11-05 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø åŒ…ę‹¬spr0096和spr2021ęŠ—åŽŸēš„čæč½½ä½“分子
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
JP6084631B2 (ja) 2011-12-08 2017-02-22 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ¼£ļ½Œļ½ļ½“ļ½”ļ½’ļ½‰ļ½„ļ½‰ļ½•ļ½ļ½„ļ½‰ļ½†ļ½†ļ½‰ļ½ƒļ½‰ļ½Œļ½…ęƒē“ ćƒ™ćƒ¼ć‚¹ć®ćƒÆć‚Æćƒćƒ³
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
CA2862247A1 (en) 2011-12-29 2013-07-04 Novartis Ag Adjuvanted combinations of meningococcal factor h binding proteins
CA2865028A1 (en) 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
EP2822584A1 (en) 2012-03-08 2015-01-14 Novartis AG Combination vaccines with tlr4 agonists
SA115360586B1 (ar) 2012-03-09 2017-04-12 ŁŲ§ŁŠŲ²Ų± Ų§Ł†Łƒ ŲŖŲ±ŁƒŁŠŲØŲ§ŲŖ Ł„Ų¹Ł„Ų§Ų¬ Ų§Ł„Ų§Ł„ŲŖŁ‡Ų§ŲØ Ų§Ł„Ų³Ų­Ų§Ų¦ŁŠ Ų§Ł„ŲØŁƒŲŖŁŠŲ±ŁŠ ŁˆŲ·Ų±Ł‚ Ł„ŲŖŲ­Ų¶ŁŠŲ±Ł‡Ų§
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
WO2013160335A2 (en) 2012-04-26 2013-10-31 Novartis Ag Antigens and antigen combinations
CA2871711A1 (en) 2012-05-04 2013-11-07 Pfizer Inc. Prostate-associated antigens and vaccine-based immunotherapy regimens
SG11201407440WA (en) 2012-05-22 2014-12-30 Novartis Ag Meningococcus serogroup x conjugate
KR102057217B1 (ko) 2012-06-20 2020-01-22 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
JP6324961B2 (ja) 2012-09-06 2018-05-16 ćƒŽćƒćƒ«ćƒ†ć‚£ć‚¹ ć‚¢ćƒ¼ć‚²ćƒ¼ 蔀ęø…ē¾¤ļ½‚é«„č†œē‚ŽčŒćØļ½„ļ¼ļ½”ļ¼ļ½ćØ恮ēµ„ćæåˆć‚ć›ćƒÆć‚Æćƒćƒ³
KR20150073160A (ko) 2012-10-03 2015-06-30 źø€ė½ģ†ŒģŠ¤ėÆøģŠ¤ķ“ė¼ģø ė°”ģ“ģ˜¤ė”œģ§€ģ¹¼ģ¦ˆ ģ—ģŠ¤.ģ—ģ“. ė©“ģ—­ģ›ģ„± ģ”°ģ„±ė¬¼
MX2015004652A (es) 2012-10-12 2015-08-05 Glaxosmithkline Biolog Sa Antigenos de pertusis acelulares no entrelazados para uso en vacunas de combinacion.
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
JP6412500B2 (ja) * 2012-10-17 2018-10-24 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
KR20140075201A (ko) * 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
KR20140075196A (ko) 2012-12-11 2014-06-19 ģ—ģŠ¤ģ¼€ģ“ģ¼€ėÆøģ¹¼ģ£¼ģ‹ķšŒģ‚¬ ė‹¤ź°€ ķė “źµ¬ź·  ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
CN105188747A (zh) 2013-02-01 2015-12-23 č‘›å…°ē“ å²åƆę–Æå…‹čŽ±ē”Ÿē‰©å…¬åø 包含tollę ·å—ä½“ęæ€åŠØ剂ēš„免ē–«ē»„合ē‰©ēš„ēš®å†…递送
JP2016521284A (ja) 2013-05-10 2016-07-21 ć‚«ćƒŖćƒ•ć‚©ćƒ«ćƒ‹ć‚¢ ć‚¤ćƒ³ć‚¹ćƒ†ć‚£ćƒćƒ„ćƒ¼ćƒˆ ć‚Ŗ惖 惆ć‚Æ惎惭ć‚øćƒ¼ 大č…øć‚¬ćƒ³ć®ćƒ—ćƒ­ćƒć‚¤ć‚Ŗćƒ†ć‚£ć‚Æć‚¹ć«ć‚ˆć‚‹é˜²ę­¢ćŠć‚ˆć³å‡¦ē½®
CA2909586C (en) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use
CN103386126B (zh) * 2013-06-25 2015-06-17 北äŗ¬ē§‘å…“ē”Ÿē‰©åˆ¶å“ęœ‰é™å…¬åø äø€ē§å«č‚ é“ē—…ęÆ’ęŠ—åŽŸēš„多价免ē–«åŽŸę€§ē»„合ē‰©
WO2015033251A2 (en) 2013-09-08 2015-03-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN114887048A (zh) 2014-01-21 2022-08-12 č¾‰ē‘žå…¬åø 包含ē¼€åˆčšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK3096783T3 (da) * 2014-01-21 2021-08-02 Pfizer Streptococcus pneumoniae-kapselpolysaccharider og konjugater deraf
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
EP3110442B1 (en) 2014-02-28 2020-10-14 GlaxoSmithKline Biologicals SA Modified meningococcal fhbp polypeptides
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北äŗ¬å¤©ęˆę–°č„‰ē”Ÿē‰©ęŠ€ęœÆęœ‰é™å…¬åø 脑膜ē‚ŽēƒčŒčšč†œå¤šē³–å•å…‹éš†ęŠ—ä½“åŠå…¶åŗ”ē”Ø
CN112851768A (zh) 2014-07-23 2021-05-28 å„„å…‹å…°å„æē«„医院及ē ”ē©¶äø­åæƒ å› å­hē»“åˆč›‹ē™½å˜ä½“及其ä½æē”Øę–¹ę³•
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
PL3244917T3 (pl) 2015-01-15 2023-07-17 Pfizer Inc. Kompozycje immunogenne do zastosowania w szczepionkach przeciwko pneumokokom
CN104548090B (zh) * 2015-01-27 2016-11-30 äø­å›½ē§‘学院čæ‡ēØ‹å·„ē؋ē ”ē©¶ę‰€ äø€ē§Ī²-葔聚ē³–äæ®é„°ēš„č„‘č†œē‚Žå¤šē³–ē»“合ē–«č‹—åŠå…¶åˆ¶å¤‡ę–¹ę³•
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
RU2721128C2 (ru) 2015-07-21 2020-05-18 ŠŸŃ„Š°Š¹Š·ŠµŃ€ Š˜Š½Šŗ. Š˜Š¼Š¼ŃƒŠ½Š¾Š³ŠµŠ½Š½Ń‹Šµ ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, сŠ¾Š“ŠµŃ€Š¶Š°Ń‰ŠøŠµ ŠŗŠ¾Š½ŃŠŃŽŠ³ŠøрŠ¾Š²Š°Š½Š½Ń‹Šµ Š°Š½Ń‚ŠøŠ³ŠµŠ½Ń‹ ŠŗŠ°ŠæсуŠ»ŃŒŠ½Š¾Š³Š¾ сŠ°Ń…Š°Ń€ŠøŠ“Š°, Š½Š°Š±Š¾Ń€Ń‹, сŠ¾Š“ŠµŃ€Š¶Š°Ń‰ŠøŠµ этŠø ŠŗŠ¾Š¼ŠæŠ¾Š·ŠøцŠøŠø, Šø Šøх ŠæрŠøŠ¼ŠµŠ½ŠµŠ½Šøя
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
CA3005524C (en) 2015-11-20 2023-10-10 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
CU24609B1 (es) 2015-12-04 2022-06-06 Dana Farber Cancer Inst Inc ProteĆ­na de fusiĆ³n que comprende una proteĆ­na de subunidad de ferritina monomĆ©rica unida a una proteĆ­na de dominio alfa 3 de mic
SI3405212T1 (sl) 2016-01-19 2020-09-30 Pfizer Inc. Cepiva proti raku
BE1024634B1 (fr) 2016-04-05 2018-05-14 Gsk Vaccines S.R.L. Compositions immunogenes
WO2017220753A1 (en) 2016-06-22 2017-12-28 MAX-PLANCK-Gesellschaft zur Fƶrderung der Wissenschaften e.V. Pneumococcal polysaccharide-protein conjugate composition
CA3031799A1 (en) 2016-08-05 2018-02-08 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112019001995A2 (pt) 2016-08-05 2019-05-07 Sanofi Pasteur, Inc. composiĆ§Ć£o de conjugado de polissacarĆ­deo pneumocĆ³cico multivalente ? proteĆ­na
JP7104027B2 (ja) 2016-09-02 2022-07-20 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  ę·‹čŒć«åÆ¾ć™ć‚‹ćƒÆć‚Æćƒćƒ³
US11478537B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
CN110022894B (zh) 2016-10-07 2024-01-19 ꁩē‰¹ē½—姆公åø ē”ØäŗŽē™Œē—‡ē–—ę³•ēš„免ē–«åŽŸę€§åŒ–合ē‰©
BE1025162B9 (fr) 2016-12-06 2019-01-07 Glaxosmithkline Biologicals Sa Procede de purification pour les polysaccharides capsulaires
HUE059252T2 (hu) 2017-01-20 2022-11-28 Pfizer ImmunogƩn kƩszƭtmƩnyek pneumokokkusz vakcinƔkban tƶrtƩnƵ alkalmazƔsra
KR20220011796A (ko) 2017-01-31 2022-01-28 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė„¤ģ“ģ„øė¦¬ģ•„ ė©”ė‹Œźø°ķ‹°ė””ģŠ¤ ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ė°©ė²•
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
KR102101879B1 (ko) * 2017-03-15 2020-05-29 ģ£¼ģ‹ķšŒģ‚¬ ģ—˜ģ§€ķ™”ķ•™ ė‹¤ź°€ ķė “źµ¬ź·  ė°±ģ‹  ģ”°ģ„±ė¬¼
BR112019020209A2 (pt) 2017-03-31 2020-06-02 Glaxosmithkline Intellectual Property Development Limited ComposiĆ§Ć£o imunogĆŖnica, uso de uma composiĆ§Ć£o imunogĆŖnica, mĆ©todo de tratamento ou prevenĆ§Ć£o de uma recorrĆŖncia de uma exacerbaĆ§Ć£o aguda de doenƧa pulmonar obstrutiva crĆ“nica, e, terapia de combinaĆ§Ć£o.
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN118356485A (zh) 2017-06-10 2024-07-19 åˆ›čµå…¬åø ęä¾›ę”¹å–„ēš„免ē–«åŽŸę€§å’Œäŗ²åˆåŠ›ēš„å…·ęœ‰äŗŒä»·ęˆ–多价ē¼€åˆē‰©å¤šē³–ēš„多价ē¼€åˆē‰©ē–«č‹—
CA3072018A1 (en) 2017-08-14 2019-02-21 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
MA51049A (fr) 2017-12-06 2020-10-14 Merck Sharp & Dohme Compositions comprenant des conjuguƩs polysaccharide-protƩine de streptococcus pneumoniae et leurs mƩthodes d'utilisation
AU2019215212A1 (en) 2018-02-05 2020-07-23 Sk Bioscience Co., Ltd. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR102486891B1 (ko) 2018-02-05 2023-01-10 ģ‚¬ė…øķ”¼ ķŒŒģŠ¤ķ‡“ė„“ ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¤ź°€ ķė “źµ¬ź· ģ„± ė‹¤ė‹¹ė„˜-ė‹Øė°±ģ§ˆ ģ ‘ķ•©ģ²“ ģ”°ģ„±ė¬¼
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
CN112118863A (zh) 2018-04-11 2020-12-22 ꁩē‰¹ē½—姆公åø ē”ØäŗŽé¢„é˜²å’Œę²»ē–—ē™Œē—‡ēš„ęŠ—åŽŸč‚½
WO2019203599A1 (ko) 2018-04-18 2019-10-24 ģ—ģŠ¤ģ¼€ģ“ė°”ģ“ģ˜¤ģ‚¬ģ“ģ–øģŠ¤ ģ£¼ģ‹ķšŒģ‚¬ ģŠ¤ķŠøė ™ķ† ģ½”ģ»¤ģŠ¤ ė‰“ėŖØė‹ˆģ•  ķ˜‘ė§‰ ė‹¤ė‹¹ė„˜ ė° ź·øģ˜ ė©“ģ—­ģ›ģ„± ģ ‘ķ•©ģ²“
US12018134B2 (en) 2018-07-19 2024-06-25 Glaxosmithkline Biological Sa Processes for preparing dried polysaccharides
CN112601545A (zh) 2018-08-07 2021-04-02 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø å·„č‰ŗ和ē–«č‹—
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
US20220016229A1 (en) 2018-12-12 2022-01-20 Pfizer Inc. Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
CN113227125A (zh) 2018-12-12 2021-08-06 č‘›å…°ē“ å²åƆäøå…‹čŽ±ę©ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽo-čæžęŽ„ēš„ē³–åŸŗ化ēš„äæ®é„°ēš„č½½ä½“č›‹ē™½
GEP20247633B (en) 2018-12-19 2024-06-25 Merck Sharp & Dohme Llc Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
US20220118072A1 (en) 2019-02-11 2022-04-21 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ćƒ•ć‚”ć‚¤ć‚¶ćƒ¼ćƒ»ć‚¤ćƒ³ć‚Æ ē“°čŒå¤šē³–锞悒ē²¾č£½ć™ć‚‹ćŸć‚ć®ę–¹ę³•
US20220184199A1 (en) 2019-04-10 2022-06-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
EP3956666A1 (en) 2019-04-18 2022-02-23 GlaxoSmithKline Biologicals S.A. Antigen binding proteins and assays
BR112021022429A2 (pt) 2019-05-10 2022-03-22 Glaxosmithkline Biologicals Sa ProduĆ§Ć£o de conjugados
CN114245746A (zh) 2019-08-05 2022-03-25 č‘›å…°ē“ å²å…‹ē”Ÿē‰©ęœ‰é™å…¬åø ē”ØäŗŽåˆ¶å¤‡åŒ…å«č›‹ē™½då¤šč‚½ēš„ē»„合ē‰©ēš„ę–¹ę³•
JP2022543281A (ja) 2019-08-05 2022-10-11 ć‚°ćƒ©ć‚Æć‚½ć‚¹ćƒŸć‚¹ć‚Æćƒ©ć‚¤ćƒ³ 惐悤ć‚Ŗ惭ć‚øć‚«ćƒ«ć‚ŗ ć‚½ć‚·ć‚Ø惆 ć‚¢ćƒŽćƒ‹ćƒ  免ē–«åŽŸę€§ēµ„ęˆē‰©
BR112022004921A2 (pt) 2019-09-27 2022-07-19 Pfizer ComposiƧƵes para neisseria meningitidis e mƩtodos das mesmas
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
CN114667343A (zh) 2019-11-01 2022-06-24 č¾‰ē‘žå¤§čÆ厂 å¤§č‚ ę†čŒē»„合ē‰©åŠå…¶ę–¹ę³•
AU2020384926A1 (en) 2019-11-15 2022-04-28 Enterome S.A. Antigenic peptides for prevention and treatment of B-cell malignancy
CA3161857A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021138495A1 (en) * 2019-12-30 2021-07-08 Fraunhofer Usa, Inc. Particles for multi-dose delivery
KR20220144393A (ko) 2020-02-21 2022-10-26 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ė‹¹ė„˜ģ˜ ģ •ģ œ
KR20220143910A (ko) 2020-02-23 2022-10-25 ķ™”ģ“ģž ģøģ½”ķ¬ė ˆģ“ķ‹°ė“œ ģ—ģŠ¤ģ¼€ė¦¬ķ‚¤ģ•„ ģ½œė¼ģ“ ģ”°ģ„±ė¬¼ ė° ź·øģ˜ ė°©ė²•
CN111588847B (zh) * 2020-05-18 2023-05-26 å¹æ州äø­åŒ»čÆ大学(å¹æ州äø­åŒ»čÆē ”ē©¶é™¢) äø€ē§å«ęœ‰å•ē£·é…ø化ēš„č„‚č“ØaäøŽē³–ęŠ—åŽŸēš„ē¼€åˆē‰©åŠå…¶åˆ¶å¤‡ę–¹ę³•å’Œåŗ”ē”Ø
WO2021250626A2 (en) 2020-06-12 2021-12-16 Glaxosmithkline Biologicals Sa Dock tag system
EP4192499A1 (en) 2020-08-10 2023-06-14 Inventprise, Inc. Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
WO2022090893A2 (en) 2020-10-27 2022-05-05 Pfizer Inc. Escherichia coli compositions and methods thereof
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
WO2022101745A2 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
TW202245836A (zh) 2021-02-19 2022-12-01 ē¾Žå•†č³½č«¾č²å·“ę–Æ德公åø 重ēµ„ļ½‚åž‹č…¦č†œē‚ŽēƒčŒē–«č‹—
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
EP4346892A2 (en) 2021-05-28 2024-04-10 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN118434441A (zh) 2021-11-18 2024-08-02 马ē‰¹é‡Œē“¦å…‹ę–Æ公åø 免ē–«åŽŸę€§čžåˆč›‹ē™½ē»„合ē‰©å’Œå…¶ä½æē”Øę–¹ę³•
CN118510548A (zh) 2022-01-13 2024-08-16 č¾‰ē‘žå…¬åø 包含ē¼€åˆēš„čšč†œē³–ęŠ—åŽŸēš„免ē–«åŽŸę€§ē»„合ē‰©åŠå…¶ē”Ø途
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives
WO2024110827A1 (en) 2022-11-21 2024-05-30 Pfizer Inc. Methods for preparing conjugated capsular saccharide antigens and uses thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations
WO2024166008A1 (en) 2023-02-10 2024-08-15 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

Family Cites Families (58)

* Cited by examiner, ā€  Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990006951A1 (en) * 1988-12-16 1990-06-28 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin mutants and pneumococcal vaccines made therefrom
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
SG90042A1 (en) 1992-06-25 2002-07-23 Smithkline Beecham Biolog Vaccine composition containing adjuvants
EP0618813B1 (en) * 1992-09-16 2002-01-09 The University Of Tennessee Research Corporation Antigen of hybrid m protein and carrier for group a streptococcal vaccine
PL178578B1 (pl) 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposĆ³b jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposĆ³b jej wytwarzania
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemĆørebetƦndelse
EP0720485B1 (en) 1993-09-22 2003-11-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ES2320315T5 (es) 1994-07-15 2012-12-05 University Of Iowa Research Foundation OligonucleĆ³tidos inmunoestimuladores
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
EP0824360A1 (en) * 1995-04-17 1998-02-25 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Š”Š¼Ń–Ń‚ŠŗŠ»Š°Š¹Š½ Š‘ічŠµŠ¼ Š‘Š°Š¹Š¾Š»Š¾Š“Š¶Ń–ŠŗŠ°Š»Ń Š”.Š. ŠšŠ¾Š¼ŠæŠ¾Š·Šøція Š²Š°ŠŗцŠøŠ½Šø (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± стŠ°Š±Ń–Š»Ń–Š·Š°Ń†Ń–Ń— qs21 Š²Ń–Š“Š½Š¾ŃŠ½Š¾ Š³Ń–Š“рŠ¾Š»Ń–Š·Ńƒ (Š²Š°Ń€Ń–Š°Š½Ń‚Šø), сŠæŠ¾ŃŃ–Š± ŠæрŠøŠ³Š¾Ń‚ŃƒŠ²Š°Š½Š½Ń ŠŗŠ¾Š¼ŠæŠ¾Š·Šøції Š²Š°ŠŗцŠøŠ½Šø
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
EP1090642B8 (en) 1995-06-07 2010-08-11 GlaxoSmithKline Biologicals s.a. Vaccines comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
SK168497A3 (en) 1995-06-07 1998-07-08 Biochem Vaccines Inc Streptococcal heat shock proteins members of the hsp70 family
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
DE69735715T2 (de) 1996-05-01 2007-03-29 The Rockefeller University Cholin-bindendes Protein, welches als gegen Pneumokokken gerichtetes Vakzin verwendet wird
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk ć‚°ćƒ¬ćƒ¼ćƒćƒ³ć‚°
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
ATE380867T1 (de) 1997-06-03 2007-12-15 Sanofi Pasteur Ltd Lactoferrinrezeptorgen von moraxella
WO1999003884A2 (en) 1997-07-21 1999-01-28 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
NZ507717A (en) 1998-04-07 2004-02-27 Medimmune Inc Derivatives of pneumococcal choline binding proteins for vaccines
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
DE69940439D1 (de) * 1998-12-21 2009-04-02 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente fĆ¼r impstoffe
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
EP1163000B1 (en) 1999-03-19 2008-02-27 GlaxoSmithKline Biologicals S.A. Vaccine against antigens from bacteriae
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 åƌ士åŗ·(ę˜†å±±)ē”µč„‘ęŽ„ę’ä»¶ęœ‰é™å…¬åø ēŗæē¼†čæžęŽ„å™Øē»„件

Also Published As

Publication number Publication date
AR022963A1 (es) 2002-09-04
HUP0200373A2 (en) 2002-06-29
NO2011014I2 (no) 2011-08-30
CZ303653B6 (cs) 2013-01-30
JP2011057713A (ja) 2011-03-24
HK1043731A1 (en) 2002-09-27
ES2300255T3 (es) 2008-06-16
HK1043728B (zh) 2007-06-22
KR20020000549A (ko) 2002-01-05
US20050031646A1 (en) 2005-02-10
TR200102739T2 (tr) 2001-12-21
DE122009000054I1 (de) 2009-12-31
JP2002540075A (ja) 2002-11-26
US20030147922A1 (en) 2003-08-07
NO20014322L (no) 2001-11-14
TR200102735T2 (tr) 2002-04-22
ATE346608T1 (de) 2006-12-15
NZ513840A (en) 2004-02-27
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
EP1776962A1 (en) 2007-04-25
IL145044A0 (en) 2002-06-30
IL145043A0 (en) 2002-06-30
SI1163000T1 (sl) 2008-06-30
WO2000056358A3 (en) 2001-01-04
EP2277535A3 (en) 2011-03-09
CY1107561T1 (el) 2013-03-13
NO20014322D0 (no) 2001-09-05
BRPI0009163B8 (pt) 2021-05-25
KR20020000785A (ko) 2002-01-05
DE60038166T2 (de) 2009-03-12
AR022965A1 (es) 2002-09-04
JP5551579B2 (ja) 2014-07-16
NO2011014I1 (no) 2011-09-19
MXPA01009452A (es) 2002-08-06
US8926985B2 (en) 2015-01-06
MY125387A (en) 2006-07-31
CN1351503A (zh) 2002-05-29
CZ20013379A3 (cs) 2002-03-13
CN1191852C (zh) 2005-03-09
EP1162998A2 (en) 2001-12-19
NO330736B1 (no) 2011-06-27
US9168313B2 (en) 2015-10-27
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
HUP0200367A2 (en) 2002-05-29
HUS1500040I1 (hu) 2018-05-28
WO2000056360A2 (en) 2000-09-28
WO2000056359A2 (en) 2000-09-28
EP1880735A2 (en) 2008-01-23
ES2339737T3 (es) 2010-05-25
PT1162999E (pt) 2007-02-28
CA2366314C (en) 2012-01-10
CY2009014I1 (el) 2010-07-28
NO20014325D0 (no) 2001-09-05
LU91652I9 (nl) 2019-01-03
BR0009163A (pt) 2001-12-26
NL300415I1 (nl) 2009-12-01
US20060093626A1 (en) 2006-05-04
EP1880735A3 (en) 2008-03-12
DK1163000T3 (da) 2008-04-28
HU228499B1 (en) 2013-03-28
CY1107390T1 (el) 2010-07-28
BRPI0009163B1 (pt) 2019-04-09
EP1163000B1 (en) 2008-02-27
FR10C0008I2 (fr) 2012-10-26
US20100119544A1 (en) 2010-05-13
AU3430700A (en) 2000-10-09
HU229968B1 (hu) 2015-03-30
DE60032120D1 (de) 2007-01-11
HK1043730A1 (zh) 2002-09-27
NZ513842A (en) 2004-05-28
KR100642044B1 (ko) 2006-11-10
PL355180A1 (en) 2004-04-05
TWI281403B (en) 2007-05-21
JP4846906B2 (ja) 2011-12-28
HK1043731B (zh) 2009-01-23
EP1163000A2 (en) 2001-12-19
NO20014323L (no) 2001-11-14
US20150079125A1 (en) 2015-03-19
CN1351501A (zh) 2002-05-29
AU750788B2 (en) 2002-07-25
AR022964A1 (es) 2002-09-04
WO2000056360A3 (en) 2001-01-25
JP2002539273A (ja) 2002-11-19
CZ20013378A3 (cs) 2002-03-13
NZ513841A (en) 2001-09-28
FR10C0008I1 (fr) 2010-03-26
WO2000056359A3 (en) 2001-02-01
DE60038166D1 (de) 2008-04-10
NO20014325L (no) 2001-11-14
US20100291138A1 (en) 2010-11-18
PL203917B1 (pl) 2009-11-30
CN1391481A (zh) 2003-01-15
TR200102736T2 (tr) 2002-04-22
JP2002540074A (ja) 2002-11-26
AU750913B2 (en) 2002-08-01
MY125202A (en) 2006-07-31
CA2366314A1 (en) 2000-09-28
BR0009154A (pt) 2001-12-26
TWI286938B (en) 2007-09-21
AU3291900A (en) 2000-10-09
HUP0200664A2 (en) 2002-06-29
WO2000056358A2 (en) 2000-09-28
NO330532B1 (no) 2011-05-09
US20060002961A1 (en) 2006-01-05
AU3813600A (en) 2000-10-09
BR0009166A (pt) 2001-12-26
PT1163000E (pt) 2008-03-20
IL145045A0 (en) 2002-06-30
EP1162999B1 (en) 2006-11-29
ATE459373T1 (de) 2010-03-15
IL145044A (en) 2007-03-08
AU750762B2 (en) 2002-07-25
ATE387214T1 (de) 2008-03-15
TWI235064B (en) 2005-07-01
DE60043930D1 (de) 2010-04-15
NO20014323D0 (no) 2001-09-05
PL355178A1 (en) 2004-04-05
EP2277535A2 (en) 2011-01-26
IL145043A (en) 2007-06-17
BE1025464I2 (nl) 2019-03-06
KR100798212B1 (ko) 2008-01-24
KR20020001785A (ko) 2002-01-09
US20110217329A1 (en) 2011-09-08
DK1162999T3 (da) 2007-03-26
DE60032120T2 (de) 2007-09-20
LU91652I2 (fr) 2010-10-13
HK1043728A1 (en) 2002-09-27
PL355264A1 (en) 2004-04-05
CZ301445B6 (cs) 2010-03-03
SI1162999T1 (sl) 2007-04-30
CY2009014I2 (el) 2010-07-28
CA2365296A1 (en) 2000-09-28
CN1192798C (zh) 2005-03-16
EP1162998B1 (en) 2010-03-03
PL204890B1 (pl) 2010-02-26
EP1162999A2 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
BE1025464I2 (nl)
JP2002514480A5 (nl)
BRPI0017527B8 (nl)
IN2001KO01233A (nl)
JP2002521141A5 (nl)
BRPI0001672A2 (nl)
JP2002517184A5 (nl)
JP2002521591A5 (nl)
JP2002519925A5 (nl)
JP2002513244A5 (nl)
JP2002506962A5 (nl)
BRPI0001542A2 (nl)
JP2002521163A5 (nl)
JP2002513606A5 (nl)
JP2002502016A5 (nl)
BRPI0012675B8 (nl)
JP2002522346A5 (nl)
BRPI0017522A2 (nl)
JP2002533952A5 (nl)
HU0004772D0 (nl)
BRMU7902607U2 (nl)
FI4323U1 (nl)
JP2001182743A5 (nl)
IN188678B (nl)
IN190455B (nl)